Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 604

1.

Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.

Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Oliviero P, Lovison F, Gucciardo G, del Turco MR, Muraca MG, Pizzichetta MA, Conforti S, Decensi A; Italian Tamoxifen Study Group.

J Natl Cancer Inst. 2007 May 2;99(9):727-37.

PMID:
17470740
2.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.

J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62.

PMID:
16288118
3.

Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.

Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Lovison F, Gucciardo G, Muraca MG, Pizzichetta MA, Conforti S, Decensi A, Robertson C, Boyle P; Italian Tamoxifen Study Group.

J Natl Cancer Inst. 2003 Jan 15;95(2):160-5.

PMID:
12529349
4.

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschênes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL.

J Natl Cancer Inst. 1996 Nov 6;88(21):1529-42.

PMID:
8901851
5.

Effects of tamoxifen on benign breast disease in women at high risk for breast cancer.

Tan-Chiu E, Wang J, Costantino JP, Paik S, Butch C, Wickerham DL, Fisher B, Wolmark N.

J Natl Cancer Inst. 2003 Feb 19;95(4):302-7.

PMID:
12591986
6.

Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).

Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Vogel VG, Dowsett M, Folkerd EJ, Willett WC, Wolmark N, Hankinson SE.

J Natl Cancer Inst. 2006 Jan 18;98(2):110-5.

PMID:
16418513
7.

Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.

Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, Runowicz CD.

Am J Obstet Gynecol. 2005 Apr;192(4):1230-7; discussion 1237-9.

PMID:
15846210
8.

Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen.

McCaskill-Stevens W, Wilson J, Bryant J, Mamounas E, Garvey L, James J, Cronin W, Wickerham DL.

J Natl Cancer Inst. 2004 Dec 1;96(23):1762-9. Erratum in: J Natl Cancer Inst. 2005 Jan 5;97(1):71.

PMID:
15572758
9.
10.

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM.

J Natl Cancer Inst. 1994 Apr 6;86(7):527-37.

PMID:
8133536
11.

Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.

Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH.

J Natl Cancer Inst. 2003 Apr 2;95(7):526-32.

PMID:
12671020
12.
13.

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N.

J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88.

PMID:
9747868
14.

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, R├╝cklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group.

J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11. Erratum in: J Natl Cancer Inst. 2008 Feb 6;100(3):226.

PMID:
18073378
15.

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR; CORE Investigators.

J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61.

16.

Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.

Abramson N, Costantino JP, Garber JE, Berliner N, Wickerham DL, Wolmark N.

J Natl Cancer Inst. 2006 Jul 5;98(13):904-10.

PMID:
16818854
18.

Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.

Vogel VG.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4413s-4418s; discussion 4411s-4412s. Review.

PMID:
11916233
19.

National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM.

Clin Cancer Res. 2003 Jan;9(1 Pt 2):495S-501S. Review.

20.

The Italian breast cancer prevention trial with tamoxifen: findings and new perspectives.

Guerrieri-Gonzaga A, Galli A, Rotmensz N, Decensi A.

Ann N Y Acad Sci. 2001 Dec;949:113-22.

PMID:
11795343

Supplemental Content

Support Center